ArriVent BioPharma, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
AVBP$13.49-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements Stockholders’ Equity (Deficit
CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(in thousands, except share data)
| | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · Accumulated · · · · · | ||||||||||||||||||
| · · · · · · · · Additional · · Other · · · · · · | ||||||||||||||||||
| · · · Common stock · · paid-in · · Comprehensive · · Accumulated · · | ||||||||||||||||||
| · · Shares · · Amount · · capital · · (Loss) · · deficit · · Total | ||||||||||||||||||
| Balance January 1, 2026 | | 42,452,251 | | $4 | | $711,847 | | $14 | | $(404,641) | | $307,224 | ||||||
| Issuance of common stock, net of issuance costs of $2,418 | | 2,425,495 | | 1 | | 54,724 | | | — | | — | | 54,725 | |||||
| Exercise of stock options | | 31,195 | | — | | 150 | | | — | | — | | 150 | |||||
| Exercise of pre-funded warrants | | | 400,000 | | | — | | | — | | | — | | | — | | | — |
| Stock-based compensation expense | | — | | — | | 5,485 | | | — | | — | | 5,485 | |||||
| Unrealized loss on marketable securities | | | — | | — | | — | | | (284) | | — | | (284) | ||||
| Net loss | | — | | — | | — | | | — | | (43,320) | | (43,320) | |||||
| Balance March 31, 2026 | | 45,308,941 | | $5 | | $772,206 | | $(270) | | $(447,961) | | $323,980 | ||||||
CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(in thousands, except share data)
| · · · · · · · · · · · · · · · · · · | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · Accumulated · · · · · | ||||||||||||||
| · · · · · · · · Additional · · Other · · · · · · | ||||||||||||||
| · · · Common stock · · paid-in · · Comprehensive · · Accumulated · · | ||||||||||||||
| · · Shares · · Amount · · capital · · (Loss) · · deficit · · Total | ||||||||||||||
| Balance January 1, 2025 | | 33,706,765 | | $3 | | $496,195 | | $(211) | | $(238,333) | | $257,654 | ||
| Issuance of common stock, net of issuance costs of $858 | | 264,458 | | 1 | | 6,516 | | | — | | — | | 6,517 | |
| Exercise of stock options | | 69,773 | | — | | 293 | | | — | | — | | 293 | |
| Stock-based compensation expense | | — | | — | | 2,271 | | | — | | — | | 2,271 | |
| Unrealized gain on marketable securities | | | — | | — | | — | | | 194 | | — | | 194 |
| Net loss | | — | | — | | — | | | — | | (64,387) | | (64,387) | |
| Balance March 31, 2025 | | 34,040,996 | | $4 | | $505,275 | | $(17) | | $(302,720) | | $202,542 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.